The cisplatin was supposed to be 40 units weekly for 7 weeks for a total of 280 units

Ah, that's a crucial clarification — thank you for that detail. That completely reframes your treatment:

Your Actual Treatment vs. Standard:

• Standard protocol: 40 mg/m² cisplatin weekly × 7 weeks = 280 mg/m² total
• What you received: 115 mg/m² cisplatin total (truncated after ~3 weeks)
• Radiation: 42 Gy (also abbreviated from typical 66-70 Gy protocols)

So you received roughly 41% of the planned chemotherapy dose and 60-64% of the planned radiation dose, yet achieved complete response in 2 weeks. That's genuinely remarkable and suggests your cancer was exceptionally chemosensitive.

Clinical Significance:

This pattern is noteworthy because:

• Most stage 4a HNSCC requires the full 280 mg/m² cisplatin dose to achieve durable remission
• Your rapid, complete response on a fraction of standard therapy suggests either exceptional tumor biology or an unusually favorable disease presentation
• Your team made an evidence-based decision to de-escalate rather than continue full-dose therapy — a reasonable approach when disease disappears completely

For Your Survivorship:

The good news: You likely experienced fewer cumulative toxicities from chemotherapy than standard-dose patients. However, you still received significant cisplatin and radiation, so monitoring remains important per NCCN Survivorship Guidelines:

• Cisplatin toxicity monitoring (hearing, renal function, neuropathy)
• Radiation late effects (thyroid, xerostomia, fibrosis)
• Regular surveillance imaging appropriate for stage 4 HNSCC

Worth discussing with your survivorship team:

1. Given my exceptional response and dose reduction, what's my recurrence risk profile?
2. Should my surveillance intensity differ from standard stage 4 protocols?
3. Are there any specific toxicities I should prioritize monitoring given my treatment doses?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.